Eli Lilly Buys AtaiBeckley in Up to $3.8 Billion Psychedelic Deal
Eli Lilly agreed to acquire psychedelics maker AtaiBeckley in a transaction valued at up to $3.8 billion. Terms include $6.75 per share in cash upfront, valuing the target at roughly $2.8 billion, plus contingent value rights worth up to $2.50 per share tied to clinical milestones.
The deal features BPL-003, an intranasal 5-MeO-DMT therapy for treatment-resistant depression that holds FDA Breakthrough Therapy designation and is in Phase 3 testing. The upfront price sets a roughly 40% premium to AtaiBeckley’s 30-day volume-weighted average price, with closing expected in the third quarter of 2026 pending regulatory approvals.
From the sources (5 posts)
@zerohedge*LILLY SAID TO NEAR DEAL FOR PSYCHEDELIC DRUGMAKER ATAIBECKLEY
@stockmktnewzEli Lilly $LLY is reportedly in talks to acquire medical psychedelic company AtaiBeckley - Bloomberg
@wallstengineEli Lilly $LLY agreed to acquire AtaiBeckley $ATAI for up to $3.8B. Terms: $6.75/share cash upfront, valuing AtaiBeckley at about $2.8B, plus a CVR worth up to $2.50/share tied to BPL-003 and VLS-01 milestones. The upfront price is a roug
@cnbcEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
@firstsquawkLILLY TO ACQUIRE ATAIBECKLEY TO ADVANCE THERAPIES FOR TREATMENT-RESISTANT DEPRESSION AND OTHER MENTAL HEALTH CONDITIONS || TO PAY $6.75 PER SHARE CASH PLUS UP TO $2.5 PER SHARE IN CVR || DEAL VALUED AT $2.8 BLN UPFRONT WITH UP TO $1 BLN IN